vs

Side-by-side financial comparison of Bioceres Crop Solutions Corp. (BIOX) and Evogene Ltd. (EVGN). Click either name above to swap in a different company.

Bioceres Crop Solutions Corp. is the larger business by last-quarter revenue ($77.6M vs $3.2M, roughly 24.0× Evogene Ltd.). Bioceres Crop Solutions Corp. runs the higher net margin — -9.6% vs -237.7%, a 228.1% gap on every dollar of revenue. On growth, Evogene Ltd. posted the faster year-over-year revenue change (40.7% vs -16.8%).

Bioceres Crop Solutions Corp is a global agricultural technology firm that develops and commercializes sustainable crop solutions including drought-tolerant seed traits, biofertilizers, and biopesticides. It serves farmers across South America, North America, Europe and Asia-Pacific, focusing on raising crop yields while reducing the environmental footprint of agricultural activities.

Evogene is a computational chemistry company based in Israel, specializing in the generative design of small molecules for the pharmaceutical and agricultural industries. At the core of its technology is ChemPass AI, a proprietary generative AI engine that enables the design of novel, highly potent small molecules optimized across multiple critical parameters. This powerful platform significantly improves success rates while reducing development time and costs. Built on this powerful technolo...

BIOX vs EVGN — Head-to-Head

Bigger by revenue
BIOX
BIOX
24.0× larger
BIOX
$77.6M
$3.2M
EVGN
Growing faster (revenue YoY)
EVGN
EVGN
+57.5% gap
EVGN
40.7%
-16.8%
BIOX
Higher net margin
BIOX
BIOX
228.1% more per $
BIOX
-9.6%
-237.7%
EVGN

Income Statement — Q1 2026 vs Q2 2025

Metric
BIOX
BIOX
EVGN
EVGN
Revenue
$77.6M
$3.2M
Net Profit
$-7.4M
$-7.7M
Gross Margin
46.8%
48.8%
Operating Margin
9.3%
-189.0%
Net Margin
-9.6%
-237.7%
Revenue YoY
-16.8%
40.7%
Net Profit YoY
-20.2%
22.0%
EPS (diluted)
$-0.12

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
BIOX
BIOX
EVGN
EVGN
Q3 25
$77.6M
Q2 25
$3.2M
Q1 25
$60.6M
Q4 24
$98.8M
Q3 24
$93.3M
Q2 24
$2.3M
Q1 24
$84.0M
Q4 23
$140.2M
Net Profit
BIOX
BIOX
EVGN
EVGN
Q3 25
$-7.4M
Q2 25
$-7.7M
Q1 25
$-1.6M
Q4 24
$605.2K
Q3 24
$-6.2M
Q2 24
$-9.8M
Q1 24
$9.8M
Q4 23
$1.2M
Gross Margin
BIOX
BIOX
EVGN
EVGN
Q3 25
46.8%
Q2 25
48.8%
Q1 25
39.4%
Q4 24
42.0%
Q3 24
40.2%
Q2 24
71.8%
Q1 24
50.8%
Q4 23
36.7%
Operating Margin
BIOX
BIOX
EVGN
EVGN
Q3 25
9.3%
Q2 25
-189.0%
Q1 25
1.5%
Q4 24
14.5%
Q3 24
2.5%
Q2 24
-409.9%
Q1 24
15.7%
Q4 23
12.0%
Net Margin
BIOX
BIOX
EVGN
EVGN
Q3 25
-9.6%
Q2 25
-237.7%
Q1 25
-2.6%
Q4 24
0.6%
Q3 24
-6.6%
Q2 24
-428.5%
Q1 24
11.6%
Q4 23
0.9%
EPS (diluted)
BIOX
BIOX
EVGN
EVGN
Q3 25
$-0.12
Q2 25
Q1 25
$-0.02
Q4 24
$0.00
Q3 24
$-0.10
Q2 24
$-1.82
Q1 24
$0.14
Q4 23
$0.00

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
BIOX
BIOX
EVGN
EVGN
Cash + ST InvestmentsLiquidity on hand
$15.5M
$8.3M
Total DebtLower is stronger
Stockholders' EquityBook value
$288.3M
$12.4M
Total Assets
$734.9M
$33.9M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
BIOX
BIOX
EVGN
EVGN
Q3 25
$15.5M
Q2 25
$8.3M
Q1 25
$38.5M
Q4 24
$29.2M
Q3 24
$32.3M
Q2 24
$9.5M
Q1 24
$16.4M
Q4 23
$24.4M
Stockholders' Equity
BIOX
BIOX
EVGN
EVGN
Q3 25
$288.3M
Q2 25
$12.4M
Q1 25
$345.0M
Q4 24
$346.3M
Q3 24
$346.0M
Q2 24
$19.9M
Q1 24
$348.5M
Q4 23
$335.3M
Total Assets
BIOX
BIOX
EVGN
EVGN
Q3 25
$734.9M
Q2 25
$33.9M
Q1 25
$798.2M
Q4 24
$835.2M
Q3 24
$827.3M
Q2 24
$41.0M
Q1 24
$836.1M
Q4 23
$819.5M

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
BIOX
BIOX
EVGN
EVGN
Operating Cash FlowLast quarter
$14.4M
$-7.5M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
BIOX
BIOX
EVGN
EVGN
Q3 25
$14.4M
Q2 25
$-7.5M
Q1 25
$23.3M
Q4 24
$-5.4M
Q3 24
$5.2M
Q2 24
$-9.6M
Q1 24
$-17.4M
Q4 23
$21.1M
Cash Conversion
BIOX
BIOX
EVGN
EVGN
Q3 25
Q2 25
Q1 25
Q4 24
-8.85×
Q3 24
Q2 24
Q1 24
-1.78×
Q4 23
17.05×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons